Communiqués Clover Biopharmaceuticals, Ltd.

Actions

2197

KYG2280A1076

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:02 04/07/2024			Varia. 5j.	Varia. 1 janv.
0,33 ^HKD	0,00 %		-4,35 %	-46,77 %

18/06	Clover Biopharmaceuticals, Ltd. annonce des résultats préliminaires positifs de la phase I pour le vaccin bivalent contre le VRS SCB-1019 chez les personnes âgées	CI
08/04	Le candidat vaccin de Clover Biopharmaceuticals contre le virus respiratoire syncytial (VRS) se révèle prometteur lors d'un essai préliminaire	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clover Announces Positive Preliminary Phase Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	19/06	AQ
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	18/06	PR
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort	08/04	PR
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)	29/12	AQ
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate	13/12	PR
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23	GL
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23	AQ
Clover Provides Updates on Business and R&D Pipeline Development	11/07/23	GL
Clover Provides Updates on Business and R&D Pipeline Development	11/07/23	AQ
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China	24/05/23	GL
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China	24/05/23	AQ
Clover Biopharmaceuticals Announces Corporate Updates and Full Year 2022 Financial Results	29/03/23	AQ
Clover Announces Corporate Updates and Full Year 2022 Financial Results	29/03/23	GL
Clover Announces Corporate Updates and Full Year 2022 Financial Results	29/03/23	AQ
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China	20/02/23	GL
Clover Biopharmaceuticals Launches COVID-19 Booster Vaccine in the People's Republic of China	15/02/23	AQ
UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China	14/02/23	GL
UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China	14/02/23	GL
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China	14/02/23	AQ
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023	16/01/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Clover Biopharmaceuticals, Ltd.

Actions

2197

KYG2280A1076

Communiqués

Filtres